BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 205788)

  • 1. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man.
    Gavras H; Brunner HR; Turini GA; Kershaw GR; Tifft CP; Cuttelod S; Gavras I; Vukovich RA; McKinstry DN
    N Engl J Med; 1978 May; 298(18):991-5. PubMed ID: 205788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of captopril (SQ 14225) on blood pressure, plasma renin activity and angiotensin I converting enzyme activity.
    Larochelle P; Genest J; Kuchel O; Boucher R; Gutkowska Y; McKinstry D
    Can Med Assoc J; 1979 Aug; 121(3):309-16. PubMed ID: 223756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive activity of captopril (SQ 14,225), an orally active inhibitor of angiotensin converting enzyme in conscious two-kidney perinephritic hypertensive dogs.
    Vollmer RR; Boccagno JA; Steinbacher TE; Horovitz ZP; Murthy VS
    J Pharmacol Exp Ther; 1981 Feb; 216(2):225-31. PubMed ID: 6257882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A discrepancy between the effects of a single oral dose of captopril on blood pressure, plasma renin activity, and serum angiotensin-converting enzyme levels.
    Lechi A; Covi G; Capuzzo MG; Lechi C; Minuz P; Delva P; Scuro LA
    Int J Clin Pharmacol Ther Toxicol; 1983 Nov; 21(11):569-74. PubMed ID: 6317579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A new principle in long-term treatment of essential hypertension: angiotensin-converting enzyme inhibition (author's transl)].
    Overlack A; Stumpe KO; Heck I; Krück F
    Dtsch Med Wochenschr; 1980 Apr; 105(15):505-9. PubMed ID: 6244920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive activity in rats for SQ 14,225, an orally active inhibitor of angiotensin I-converting enzyme.
    Laffan RJ; Goldberg ME; High JP; Schaeffer TR; Waugh MH; Rubin B
    J Pharmacol Exp Ther; 1978 Feb; 204(2):281-8. PubMed ID: 202693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects.
    Lewis RA; Baker KM; Ayers CR; Weaver BA; Lehman MR
    J Cardiovasc Pharmacol; 1985; 7 Suppl 1():S12-5. PubMed ID: 2580164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical experience with a new antihypertensive drug (captopril SQ 14.225), an oral inhibitor of converting enzyme].
    Santucci A; Aguglia F; Ficara C
    Clin Ter; 1981 Apr; 97(1):43-58. PubMed ID: 6269793
    [No Abstract]   [Full Text] [Related]  

  • 9. [Potentiation of the antihypertensive effect of captopril by diuretics (author's transl)].
    Waeber B; Brunner HR; Turini GA; Curtet N; Keller I; Gavras H
    Ann Cardiol Angeiol (Paris); 1979; 28(1):9-11. PubMed ID: 219758
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.
    Davis R; Ribner HS; Keung E; Sonnenblick EH; LeJemtel TH
    N Engl J Med; 1979 Jul; 301(3):117-21. PubMed ID: 221810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Innappropriate renin secretion unmasked by captopril (SQ 14 225) in hypertension of chronic renal failure.
    Brunner HR; Waeber B; Wauters JP; Turin G; McKinstry D; Gavras H
    Lancet; 1978 Sep; 2(8092 Pt 1):704-7. PubMed ID: 80634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Captopril in primary hypertension. Effects related to the renin-angiotensin-aldosterone and kallikrein-kinin systems.
    Ohman KP; Karlberg BE; Nilsson OR; Wettre S
    Acta Med Scand Suppl; 1981; 646():98-105. PubMed ID: 7018190
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of moderate to severe hypertensive patients with an orally active converting-enzyme inhibitor.
    Prins EJ; Donker AJ; Hoorntje SJ; Leenen FH; van der Hem GK
    Proc Eur Dial Transplant Assoc; 1979; 16():603-9. PubMed ID: 232914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long term treatment of resistant hypertension with captopril (author's transl)].
    Guedon J; Chaignon M; Lucsko M; Cuche JL; Aubert P; Piete AM
    Nouv Presse Med; 1981 Apr; 10(19):1565-9. PubMed ID: 7025846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of angiotensin-converting enzyme inhibition on plasma aldosterone concentration, plasma renin activity, and blood pressure in spontaneously hypertensive cats with chronic renal disease.
    Steele JL; Henik RA; Stepien RL
    Vet Ther; 2002; 3(2):157-66. PubMed ID: 19750747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antihypertensive therapy with MK 421: angiotensin II--renin relationships to evaluate efficacy of converting enzyme blockade.
    Biollaz J; Brunner HR; Gavras I; Waeber B; Gavras H
    J Cardiovasc Pharmacol; 1982; 4(6):966-72. PubMed ID: 6185790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
    Tiryaki O; Usalan C; Buyukhatipoglu H
    Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of severe arterial hypertension with captopril (SQ 14.225) (author's transl)].
    Di Giulio S; Perez-Ramirez JL; Jamoun P; Grünfeld JP; Meyer P
    Nouv Presse Med; 1981 Apr; 10(19):1551-5. PubMed ID: 6269557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure.
    McMurray JJ; Pitt B; Latini R; Maggioni AP; Solomon SD; Keefe DL; Ford J; Verma A; Lewsey J;
    Circ Heart Fail; 2008 May; 1(1):17-24. PubMed ID: 19808266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.